From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

NextBio Awarded $26M for Broad-Spectrum Influenza Phase 2

by Global Biodefense Staff
September 27, 2012

The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness & Response (ASPR) this week awarded $26,504,502.00 to NextBio, Incorporated, for advancement of a broad-spectrum antiviral therapeutic for treatment of Influenza A & B.

The major goal of the contract is to successfully complete a Phase 2B clinical trial which will advance candidate DAS181, an inhaled recombinant fusion protein, towards Federal Drug Administration NDA filing and approval.

DAS181 is a broad spectrum drug candidate for treatment and prevention of Influenza-Like Illness (ILI) caused by any strain of influenza and parainfluenza viruses. Unlike neuraminidase inhibitors, as well as vaccines which target the influenza virus, DAS181 works by inactivating the human receptors for these viruses. This mechanism of action makes DAS181 less likely to cause drug resistance compared with currently-available antiviral drugs.

The award is a Cost Plus Fixed Fee (CPFF) type Research and Development contract under the procedures of a Broad Agency Announcement (BAA). Further details are available under Solicitation Number: BAA-11-100-SOL-00021.

NextBio is headquartered in Santa Clara, CA.

From Our Partners
Tags: AntiviralsASPRAwardsHHSInfluenza

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC